Wedbush Reiterates "Outperform" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)

Wedbush Reiterates "Outperform" Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)

Wedbush restated an "outperform" rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a research note on Thursday.

Traders Buy Large Volume of ORIC Pharmaceuticals Call Options (NASDAQ:ORIC)

ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC – Get Free Report) was the recipient of unusually large options trading on Thursday. Stock investors bought 8,284 call options on the stock. This is an increase of 3,533% compared to the typical volume of 228 call options. ORIC Pharmaceuticals Trading Up 33.5% Shares of ORIC opened at $7.97 on Friday. The stock has a 50 day moving average of $5.35 and a 200 day moving average of $7.72. ORIC Pharmaceuticals…

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a 133.83% Potential Upside in Biotech Innovation

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) is making waves in the biotechnology sector with its innovative approach to tackling cancer resistance mechanisms. With a market capitalization of $566.57 million, this clinical-stage biopharmaceutical company is focused on developing therapies that push the frontiers of cancer treatment. As ORIC’s stock currently trades at $7.97, investors are keenly eyeing its potential, especially given an impressive …